Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/26463
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDe Marco, M-
dc.contributor.authorBocchetta, M-
dc.contributor.authorVenneri, A-
dc.contributor.otherAlzheimer’s Disease Neuroimaging Initiative-
dc.date.accessioned2023-05-17T12:43:50Z-
dc.date.available2023-05-17T12:43:50Z-
dc.date.issued2023-05-16-
dc.identifierORCID iDs: Matteo De Marco https://orcid.org/0000-0003-1814-5024; Martina Bocchetta https://orcid.org/0000-0003-1814-5024; Annalena Venneri https://orcid.org/0000-0002-9488-2301.-
dc.identifier806-
dc.identifier.citationDe Marco, M., Bocchetta, M. and Venneri, A. on behalf of the Alzheimer’s Disease Neuroimaging Initiative (2023) 'Item-Level Scores on the Boston Naming Test as an Independent Predictor of Perirhinal Volume in Individuals with Mild Cognitive Impairment', Brain Sciences, 13 (5), 806, pp.1 - 17. doi: 10.3390/brainsci13050806.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/26463-
dc.descriptionData Availability Statement: All data are publicly available at https://adni.loni.usc.edu/.en_US
dc.descriptionSupplementary Materials: The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/brainsci13050806/s1: Figure S1: Structural covariance maps of mediotemporal regions of interest (ROIs).-
dc.description.abstractCopyright © 2023 by the authors. We explored the methodological value of an item-level scoring procedure applied to the Boston Naming Test (BNT), and the extent to which this scoring approach predicts grey matter (GM) variability in regions that sustain semantic memory. Twenty-seven BNT items administered as part of the Alzheimer’s Disease Neuroimaging Initiative were scored according to their “sensorimotor interaction” (SMI) value. Quantitative scores (i.e., the count of correctly named items) and qualitative scores (i.e., the average of SMI scores for correctly named items) were used as independent predictors of neuroanatomical GM maps in two sub-cohorts of 197 healthy adults and 350 mild cognitive impairment (MCI) participants. Quantitative scores predicted clusters of temporal and mediotemporal GM in both sub-cohorts. After accounting for quantitative scores, the qualitative scores predicted mediotemporal GM clusters in the MCI sub-cohort; clusters extended to the anterior parahippocampal gyrus and encompassed the perirhinal cortex. This was confirmed by a significant yet modest association between qualitative scores and region-of-interest-informed perirhinal volumes extracted post hoc. Item-level scoring of BNT performance provides complementary information to standard quantitative scores. The concurrent use of quantitative and qualitative scores may help profile lexical–semantic access more precisely, and might help detect changes in semantic memory that are typical of early-stage Alzheimer’s disease.en_US
dc.description.sponsorshipThis research was supported by an Alzheimer’s Association Research Grant (23AARG-1030190) to MDM. MB is supported by a Fellowship award from the Alzheimer’s Society, UK (AS-JF-19a-004-517). AV is supported by funding obtained under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3—Call for tender No. 341 of 15/03/2022 of the Italian Ministry of University and Research funded by the European Union—NextGenerationEU, Project code PE0000006, Concession Decree No. 1553 of 11/10/2022 adopted by the Italian Ministry of University and Research, CUP D93C22000930002, “A multiscale integrated approach to the study of the nervous system in health and disease” (MNESYS). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organisation is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.en_US
dc.format.extent1 - 17-
dc.format.mediumElectronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherMDPIen_US
dc.rightsCopyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectbody–object interactionen_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectsemantic memoryen_US
dc.subjectconfrontational naming;en_US
dc.subjectlexical abilitiesen_US
dc.subjectMRIen_US
dc.subjectneuroimagingen_US
dc.titleItem-Level Scores on the Boston Naming Test as an Independent Predictor of Perirhinal Volume in Individuals with Mild Cognitive Impairmenten_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/brainsci13050806-
dc.relation.isPartOfBrain Sciences-
pubs.issue5-
pubs.publication-statusPublished online-
pubs.volume13-
dc.identifier.eissn2076-3425-
dc.rights.holderThe authors-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).1.09 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons